Table 1.

Description of demographics, clinical phenotype, symptoms, and endoscopic activity in patients in the NIDA-IBD cohort.

	CD [n = 100]	UC [n = 72]
Mean age [SD, years]	45.2 [14]	49.5 [14]
Female participants [%]	53 [53.0]	38 [52.8]
Median time since IBD diagnosis [range, years]	13.00 [0–43]	11.50 [0–54]
NZ European ethnicity [%]	100 [100]	69 [95.8]
Montreal classification of CD [%]
A1 [%]	7 [7]
A2 [%]	75 [75]
A3 [%]	18 [18]
L1 [%]	18 [18]
L2 [%]	21 [21]
L3 [%]	61 [61]
B1 [%]	60 [60]
B2 [%]	20 [20]
B3 [%]	20 [20]
Perianal disease [%]	17 [17]
Montreal classification of UC
E1 [%]		6 [8.3]
E2 [%]		33 [45.8]
E3 [%]		33 [45.8]
Endoscopic remission [%] SES-CD ≤ 2, UCEIS < 2	38 [38]	37 [51.4]
Endoscopically active IBD [%] SES-CD > 2, UCEIS ≥ 2	62 [62]	35 [48.6]
Mild endoscopic activity [%]	34 [34]	22 [30.6]
Moderate endoscopic activity [%]	19 [19]	7 [9.7]
Severe endoscopic activity [%]	9 [9]	6 [8.3]
Median C-reactive protein [mg/L, IQR]	3.0 [0–6.8]	3.0 [0–6.0]
Medianfaecal calprotectin[μg/g, IQR]	115.6 [45.8–350.3]	146.1 [45.2–853.1]
Median faecal myeloperoxidase [μg/g, IQR]	10.1 [3.0–44.4]	15.6 [1.7–107.5]
Median SES-CD [IQR]	3.0 [0.0–8.5]
Median UCEIS [IQR]		1.0 [0.0–4.0]
Median HBI [IQR]	6.0 [3.0–10.8]
Median CDAI [IQR]	119.5 [54.3–213.3]
Median SCCAI [IQR]		4.5 [2.0–8.0]
Mean IBDQ-32 [SD]	161.37 [37, 32]	166.13 [40, 29]

CD ,  Crohn’s disease; UC ,  ulcerative colitis; IBD ,  inflammatory bowel disease; SES-CD ,  Simple Endoscopic Score for CD; UCEIS ,  UC Endoscopic Index of Severity; HBI ,  Harvey–Bradshaw Index; SCCAI ,  Simple Clinical Colitis Activity Index; IBDQ-32 ,  Inflammatory Bowel Diseases Questionnaire; IQR, interquartile range; NZ, New Zealand; SD, standard deviation.